AVANIR to Present at the Canaccord Genuity Growth Conference

ALISO VIEJO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the Company will present at the 30th Annual Canaccord Genuity Growth Conference on Tuesday, August 10th at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) at the InterContinental Hotel in Boston.  The Canaccord Genuity Growth Conference provides participating companies with the opportunity to present to institutional investors and industry leaders.  

A live audio webcast of the presentation will be available by visiting AVANIR'S website at www.avanir.com.  To listen to the live presentation, please go to AVANIR'S website prior to the start of the presentation to register, download and install the necessary software.  An archive of the presentation at the Canaccord Genuity Growth Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.  As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.  For more information about AVANIR, please visit www.avanir.com.  

SOURCE AVANIR Pharmaceuticals, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.